The global continuous renal replacement therapy market revenue was around US$ 1.5 billion in 2021 and is estimated to reach US$ 2.8 billion by 2031, growing at a compound annual growth rate (CAGR) of ...

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter ...

The Prismaflex (Gambro, Lakewood, CO) integrated CRRT system was introduced to our hospital and used to provide renal replacement therapy for ECLS patients in April 2009. Prior to this time ...

On April 19, 2025, the Blood Purification Professional Committee (BPPC) of the China Medical Device Industry Association (CMDIA) gathered in Liuyang, Hunan, for its annual conference, themed "Synergy ...

The Department of Nephrology and Dialysis opened at the Okhmatdyt Polyclinic (Kyiv) within the cooperation between the ...

The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70 patients, of which 6 patients are already enrolled Talphera believes the ...

If approved, Niyad would become the only FDA approved regional anticoagulant for use during continuous renal replacement therapy. We believe this profile would be impactful given the many ...

CytoSorbents Corporation , a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Melanie ...